CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses CheckMate 067, a randomised, double-blind, phase 3 trial of nivolumab monotherapy or nivolumab combined with ipilimumab versus ipilimumab monotherapy in patients with previously untreated unresectable or metastatic melanoma.

Year of Production:
Running Time:
Color/Sound:

2015
01:55
Color/Sound

Comments are closed.